Effect of sirolimus withdrawal in patients with deteriorating renal function

American Journal of Transplantation

Volumn 4, Issue 10, 2004, Pages 1709-1712

  Kaplan, Bruce ^a   Schold, Jesse ^a   Srinivas, Titte ^a   Womer, Karl ^a   Foley, David P ^a   Patton, Pamela ^a   Howard, Richard ^a   Meier Kriesche, Herwig Ulf ^a  

^a UNIVERSITY OF FLORIDA   (United States)

Author keywords

Renal function; Sirolimus; Transplant

Indexed keywords

CALCINEURIN INHIBITOR; CREATINE; CYCLOSPORIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; TACROLIMUS;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; DETERIORATION; DRUG EFFECT; DRUG WITHDRAWAL; FEMALE; HEMATOCRIT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; MALE; NEPHROTOXICITY; PRIORITY JOURNAL;

ADULT; CALCINEURIN; CREATININE; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; MALE; MYCOPHENOLIC ACID; SIROLIMUS; TIME FACTORS; WITHHOLDING TREATMENT;

EID: 4744351965     PISSN: 16006135     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2004.00569.x     Document Type: Article

References (14)

1. Flechner SM, Goldfarb D, Modlin C et al. Kidney transplantation without calcineurin inhibitor drugs: A prospective, randomized trial of sirolimus versus cyclosporine. Transplantation 2002; 74: 1070-1076.
2. Baboolal K. A phase III prospective, randomized study to evaluate concentration-controlled sirolimus (rapamune) with cyclosporine dose minimization or elimination at six months in de novo renal allograft recipients. Transplantation 2003; 75: 1404-1408.
3. Gonwa TA, Hricik DE, Brinker K, Grinyo JM, Schena FP. Improved renal function in sirolimus-treated renal transplant patients after early cyclosporine elimination. Transplantation 2002; 74: 1560-1567.
4. Kahan BD, Kramer WG. Median effect analysis of efficacy versus adverse effects of immunosuppressants. Clin Pharmacol Ther 2001; 70: 74-81.
5. Oberbauer R, Kreis H, Johnson RW et al. Long-term improvement in renal function with sirolimus after early cyclosporine withdrawal in renal transplant recipients: 2-year results of the Rapamune Maintenance Regimen Study. Transplantation 2003; 76: 364-370.
6. Kreis H, Oberbauer R, Campistol JM et al. Long-term benefits with sirolimus-based therapy after early cyclosporine withdrawal. J Am Soc Nephrol 2004; 15: 809-817.
7. Morales JM, Wramner L, Kreis H et al. Sirolimus does not exhibit nephrotoxicity compared to cyclosporine in renal transplant recipients. Am J Transplant 2002; 2: 436-442.
8. Shihab FS, Bennett WM, Yi H, Choi SO, Andoh TF. Sirolimus increases transforming growth factor-beta1 expression and potentiates chronic cyclosporine nephrotoxicity. Kidney Int 2004; 65: 1262-1271.
9. Kahan BD for the The Rapamune US Study Group. Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: A randomised multicentre study. Lancet 2000; 356: 194-202.
10. MacDonald AS for the Rapamune Global Study Group. A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts. Transplantation 2001; 71: 271-280.
11. Bennett WM, Pulliam JP. Cyclosporine nephrotoxicity. Ann Intern Med 1983; 99: 851-854.
12. Nankivell BJ, Borrows RJ, Fung CL, O'Connell PJ, Allen RD, Chapman JR. The natural history of chronic allograft nephropathy. N Engl J Med 2003; 349: 2326-2333.
13. Chueh SC, Kahan BD. Dyslipidemia in renal transplant recipients treated with a sirolimus and cyclosporine-based immunosuppressive regimen: Incidence, risk factors, progression, and prognosis. Transplantation 2003; 76: 375-382.
14. Weir MR, Ward MT, Blahut SA et al. Long-term impact of discontinued or reduced calcineurin inhibitor in patients with chronic allograft nephropathy. Kidney Int 2001; 59: 1567-1573.